Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: Biological and clinical evidence

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Endometriosis-associated symptomatology can be safely and effectively treated with intrauterine-released progestin, which is associated with fewer adverse effects than other therapeutic options and may be used on a long-term basis. We have herein reviewed the current literature in relation to the biological and clinical rationale for the use of an intrauterine system releasing 20 μg/day of levonorgestrel for the treatment of pelvic pain symptoms associated with endometriosis. Levonorgestrel induces endometrial glandular atrophy and decidual transformation of the stroma, reduces endometrial cell proliferation and increases apoptotic activity. After the first year of use, a 70-90% reduction in menstrual blood loss is observed. The levonorgestrel-releasing intrauterine system has proven effective in relieving pelvic pain symptoms caused by peritoneal and rectovaginal endometriosis and in reducing the risk of recurrence of dysmenorrhea after conservative surgery. Thus, the intrauterine delivery of a potent progestin may constitute an innovative, effective, safe and convenient alternative for local delivery of a potent progestin in the long-term therapy of symptomatic endometriosis.

Original languageEnglish
Pages (from-to)207-214
Number of pages8
JournalWomen's Health
Volume3
Issue number2
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Levonorgestrel
Endometriosis
Progestins
Pelvic Pain
Dysmenorrhea
Therapeutic Uses
Therapeutics
Atrophy
Cell Proliferation
Recurrence

Keywords

  • Dysmenorrhea
  • Dyspareunia
  • Endometriosis
  • Levonorgestrel-releasing intrauterine system
  • Pelvic pain
  • Progestins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{41bba7e4e491456fb5a49a07c7fd047e,
title = "Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: Biological and clinical evidence",
abstract = "Endometriosis-associated symptomatology can be safely and effectively treated with intrauterine-released progestin, which is associated with fewer adverse effects than other therapeutic options and may be used on a long-term basis. We have herein reviewed the current literature in relation to the biological and clinical rationale for the use of an intrauterine system releasing 20 μg/day of levonorgestrel for the treatment of pelvic pain symptoms associated with endometriosis. Levonorgestrel induces endometrial glandular atrophy and decidual transformation of the stroma, reduces endometrial cell proliferation and increases apoptotic activity. After the first year of use, a 70-90{\%} reduction in menstrual blood loss is observed. The levonorgestrel-releasing intrauterine system has proven effective in relieving pelvic pain symptoms caused by peritoneal and rectovaginal endometriosis and in reducing the risk of recurrence of dysmenorrhea after conservative surgery. Thus, the intrauterine delivery of a potent progestin may constitute an innovative, effective, safe and convenient alternative for local delivery of a potent progestin in the long-term therapy of symptomatic endometriosis.",
keywords = "Dysmenorrhea, Dyspareunia, Endometriosis, Levonorgestrel-releasing intrauterine system, Pelvic pain, Progestins",
author = "Paola Vigan{\`o} and Edgardo Somigliana and Paolo Vercellini",
year = "2007",
month = "3",
doi = "10.2217/17455057.3.2.207",
language = "English",
volume = "3",
pages = "207--214",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Levonorgestrel-releasing intrauterine system for the treatment of endometriosis

T2 - Biological and clinical evidence

AU - Viganò, Paola

AU - Somigliana, Edgardo

AU - Vercellini, Paolo

PY - 2007/3

Y1 - 2007/3

N2 - Endometriosis-associated symptomatology can be safely and effectively treated with intrauterine-released progestin, which is associated with fewer adverse effects than other therapeutic options and may be used on a long-term basis. We have herein reviewed the current literature in relation to the biological and clinical rationale for the use of an intrauterine system releasing 20 μg/day of levonorgestrel for the treatment of pelvic pain symptoms associated with endometriosis. Levonorgestrel induces endometrial glandular atrophy and decidual transformation of the stroma, reduces endometrial cell proliferation and increases apoptotic activity. After the first year of use, a 70-90% reduction in menstrual blood loss is observed. The levonorgestrel-releasing intrauterine system has proven effective in relieving pelvic pain symptoms caused by peritoneal and rectovaginal endometriosis and in reducing the risk of recurrence of dysmenorrhea after conservative surgery. Thus, the intrauterine delivery of a potent progestin may constitute an innovative, effective, safe and convenient alternative for local delivery of a potent progestin in the long-term therapy of symptomatic endometriosis.

AB - Endometriosis-associated symptomatology can be safely and effectively treated with intrauterine-released progestin, which is associated with fewer adverse effects than other therapeutic options and may be used on a long-term basis. We have herein reviewed the current literature in relation to the biological and clinical rationale for the use of an intrauterine system releasing 20 μg/day of levonorgestrel for the treatment of pelvic pain symptoms associated with endometriosis. Levonorgestrel induces endometrial glandular atrophy and decidual transformation of the stroma, reduces endometrial cell proliferation and increases apoptotic activity. After the first year of use, a 70-90% reduction in menstrual blood loss is observed. The levonorgestrel-releasing intrauterine system has proven effective in relieving pelvic pain symptoms caused by peritoneal and rectovaginal endometriosis and in reducing the risk of recurrence of dysmenorrhea after conservative surgery. Thus, the intrauterine delivery of a potent progestin may constitute an innovative, effective, safe and convenient alternative for local delivery of a potent progestin in the long-term therapy of symptomatic endometriosis.

KW - Dysmenorrhea

KW - Dyspareunia

KW - Endometriosis

KW - Levonorgestrel-releasing intrauterine system

KW - Pelvic pain

KW - Progestins

UR - http://www.scopus.com/inward/record.url?scp=33947693200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947693200&partnerID=8YFLogxK

U2 - 10.2217/17455057.3.2.207

DO - 10.2217/17455057.3.2.207

M3 - Article

C2 - 19803853

AN - SCOPUS:33947693200

VL - 3

SP - 207

EP - 214

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 2

ER -